Adenovirus-mediated intralesional interferon-γ gene transfer induces tumor regressions in cutaneous lymphomas

Blood

Volumn 104, Issue 6, 2004, Pages 1631-1638

  Dummer, Reinhard ^a   Hassel, Jessica C ^b   Fellenberg, Friederike ^b   Eichmüller, Stefan ^b   Maier, Tanja ^b   Slos, Philippe ^b   Acres, Bruce ^b   Bleuzen, Pascal ^b   Bataille, Vincent ^b   Squiban, Patrick ^b   Burg, Günter ^b   Urosevic, Mirjana ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GAMMA INTERFERON; TG 1042; TUMOR ANTIGEN; TUMOR ANTIGEN SE70 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTHENIA; B CELL LYMPHOMA; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COLD SENSATION; COLITIS; COUGHING; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; EPISTAXIS; ERYTHEMA; EXFOLIATIVE DERMATITIS; FATIGUE; FEMALE; FEVER; FLUSHING; GASTROINTESTINAL SYMPTOM; GENE; GENE EXPRESSION; GENE TRANSFER; HEADACHE; HEART ARRHYTHMIA; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INJECTION SITE; INTERFERON GAMMA GENE; LIMB PAIN; LYMPHADENOPATHY; MALAISE; MALE; MOTOR DYSFUNCTION; NAUSEA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SKIN DEFECT; SKIN INDURATION; SKIN LYMPHOMA; SLEEP DISORDER; SWEATING; TACHYCARDIA; TH2 CELL; TISSUE SECTION; TRANSGENE; TUMOR REGRESSION; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE;

EID: 4444349308     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-01-0360     Document Type: Article

References (33)

1. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997;90:354-371.
2. Dummer R, Willers J, Kamarashev J, Urosevic M, Dobbeling U, Burg G. Pathogenesis of cutaneous lymphomas. Semin Cutan Med Surg. 2000;19:78-86.
3. Rook AH, Gottlieb SL, Wolfe JT, et al. Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis. Clin Exp Immunol. 1997;107(suppl 1):16-20.
4. Dalloul A, Laroche L, Bagot M, et al. Interleukin-7 is a growth factor for Sezary lymphoma cells. J Clin Invest. 1992;90:1054-1060.
5. Dobbeling U, Dummer R, Laine E, Potoczna N, Qin JZ, Burg G. Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood. 1998;92:252-258.
6. Vowels BR, Cassin M, Vonderheid EC, Rook AH. Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol. 1992;99:90-94.
7. Asadullah K, Docke WD, Haeussler A, Sterry W, Volk HD. Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. J Invest Dermatol. 1996;107:833-837.
8. Dummer R, Heald PW, Nestle FO, et al. Sezary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). Blood. 1996;88:1383-1389.
9. Laroche L, Kaiserlian D. Decreased natural-killer-cell activity in cutaneous T-cell lymphomas. N Engl J Med. 1983;308:101-102.
10. Asadullah K, Gellrich S, Haeussler Quade A, et al. Cytokine expression in primary cutaneous germinal center cell lymphomas. Exp Dermatol. 2000;9:71-76.
11. Bunn PA Jr, Foon KA, Ihde DC, et al. Recombinant leukocyte A Interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med. 1984;101:484-487.
12. Kaplan EH, Rosen ST, Norris DB, Roenigk HH Jr, Saks SR, Bunn PA Jr. Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst. 1990;82:208-212.
13. Rook AH, Wood GS, Yoo EK, et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood. 1999;94:902-908.
14. Dummer R, Urosevic M, Kempt W, Kazakov D, Burg G. Imiquimod induces complete clearance of a PUVA-resistant plaque in Mycosis Fungoides. Dermatology. 2003;207:116-118.
15. Urosevic M, Willers J, Mueller B, Kempf W, Burg G, Dummer R. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood. 2002;99:609-617.
16. Slos P, De Meyer M, Leroy P, Rousseau C, Acres B. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity. Cancer Gene Ther. 2001;8:321-332.
17. Eichmuller S, Usener D, Dummer R, Stein A, Thiel D, Schadendorf D. Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci U S A. 2001;98:629-634.
18. Rook AH, Junkins-Hopkins JM, McGinnis KS, et al. Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma. Adv Dermatol. 2002;18:29-43.
19. Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995;9:1089-1107.
20. Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002;13:95-109.
21. Seo N, Tokura Y, Matsumoto K, Furukawa F, Takigawa M. Tumour-specific cytotoxic T lymphocyte activity in Th2-type Sezary syndrome: its enhancement by interferon-gamma (IFN-gamma) and IL-12 and fluctuations in association with disease activity. Clin Exp Immunol. 1998;112:403-409.
22. Jimbow K, Yamana K, Ishida O, Kawamura M, Ito Y, Maeda K. Evaluation of rIFN-gamma in the treatment of lymphoma and melanoma of the skin by systemic and intralesional administration. Gan To Kagaku Ryoho. 1987;14:152-158.
23. Berger CL, Wang N, Christensen I, Longley J, Heald P, Edelson RL. The immune response to class I-associated tumor-specific cutaneous T-Cell lymphoma antigens. J Invest Dermatol. 1996;107:392-397.
24. Berger CL, Longley BJ, Imaeda S, Christensen I, Heald P, Edelson RL. Tumor-specific peptides in cutaneous T-cell lymphoma: association with class I major histocompatibility complex and possible derivation from the clonotypic T-cell receptor. Int J Cancer. 1998;76:304-311.
25. Bagot M, Echchakir H, Mami-Chouaib F, et al. Isolation of tumor-specific cytotoxic CD4+ and CD4+CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma. Blood. 1998;91:4331-4341.
26. Echchakir H, Bagot M, Dorothee G, et al. Cutaneous T cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a fas-independent pathway for specific tumor cell lysis. J Invest Dermatol. 2001;115:74-80.
27. Trudel S, Li Z, Dodgson C, et al. Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma - a phase 1 study. Leukemia. 2001;15:846-854.
28. Mentel R, Dopping G, Wegner U, Seidel W, Liebermann H, Dohner L. Adenovirus-receptor interaction with human lymphocytes. J Med Virol. 1997;51:252-257.
29. Higginbotham JN, Seth P, Blaese RM, Ramsey WJ. The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid. Hum Gene Ther. 2002;13:129-141.
30. Berdowska A, Zwirska-Korczala K. Neopterin measurement in clinical diagnosis. J Clin Pharm Ther. 2001;26:319-329.
31. St George JA. Gene therapy progress and prospects: adenoviral vectors. Gene Ther. 2003;10:1135-1141.
32. Franzke A, Peest D, Probst-Kepper M, et al. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol. 1999;17:529-533.
33. Weijl NI, Van der Harst D, Brand A, et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol. 1993;11:1376-1383.